Osteonecrosis of the jaw related to sunitinib. (Q54680163)

2 June 2018

title

Osteonecrosis of the jaw related to sunitinib. (English)

1 reference

2 June 2018

author

Christian Walter

2

1 reference

2 June 2018

author name string

Felix P Koch

1

1 reference

2 June 2018

Torsten Hansen

3

1 reference

2 June 2018

Elke Jäger

4

1 reference

2 June 2018

Wilfried Wagner

5

1 reference

2 June 2018

publication date

1 March 2011

1 reference

2 June 2018

Oral and maxillofacial surgery

published in

1 reference

2 June 2018

volume

15

1 reference

2 June 2018

issue

1

1 reference

2 June 2018

page(s)

63-66

1 reference

2 June 2018

https://scigraph.springernature.com/pub.10.1007/s10006-010-0224-y

exact match

0 references

cites work

Sunitinib: from rational design to clinical efficacy

1 reference

https://api.crossref.org/works/10.1007%2FS10006-010-0224-Y

Tyrosine kinase inhibitors and anti-angiogenic therapies in kidney cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10006-010-0224-Y

Role of tyrosine kinase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10006-010-0224-Y

Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10006-010-0224-Y

Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10006-010-0224-Y

Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10006-010-0224-Y

Osteoradionecrosis of the jaws--a current overview--part 1: Physiopathology and risk and predisposing factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10006-010-0224-Y

Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10006-010-0224-Y

Osteonecrosis of the jaws by long term therapy with bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10006-010-0224-Y

Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10006-010-0224-Y

Flt3 receptor tyrosine kinase as a drug target in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10006-010-0224-Y

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10006-010-0224-Y

The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10006-010-0224-Y

Sunitinib: a cause of bullous palmoplantar erythrodysesthesia, periungual erythema, and mucositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10006-010-0224-Y

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10006-010-0224-Y

Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10006-010-0224-Y

Actinomycosis of the jaws--histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10006-010-0224-Y

Pharmacokinetics of vinorelbine in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10006-010-0224-Y

Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects.

21 January 2018

1 reference

12 December 2020

Osteonecrosis of the jaw, a recently recognized sequela of bisphosphonate therapy: case report

1 reference

12 December 2020

New foundations in understanding osteonecrosis of the jaws

1 reference

12 December 2020

Pharmacokinetic and pharmacological aspects of interferon therapy in man

1 reference

12 December 2020

Sunitinib and Hypothyroidism

1 reference

12 December 2020

Microvascular pericytes express platelet-derived growth factor-beta receptors in human healing wounds and colorectal adenocarcinoma.

1 reference

12 December 2020

Osteonecrosis of the jaws: a complication of cancer chemotherapy

1 reference

12 December 2020

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

1 reference

12 December 2020

10.1007/S10006-010-0224-Y

Identifiers

DOI

1 reference

2 June 2018

1 reference

2 June 2018